PMID- 35041313
OWN - NLM
STAT- MEDLINE
DCOM- 20220120
LR  - 20221207
IS  - 1997-7298 (Print)
IS  - 1997-7298 (Linking)
VI  - 121
IP  - 12
DP  - 2021
TI  - [Fluvoxamine in the treatment of depressive disorders in alcohol dependence: 
      results of randomized open-label comparative study].
PG  - 57-62
LID - 10.17116/jnevro202112112157 [doi]
AB  - OBJECTIVE: Assess the efficacy and safety of fluvoxamine, sertraline, citalopram, 
      paroxetine, fluoxetine. MATERIAL AND METHODS: The study included 175 patients 
      with alcohol dependence and depressive disorders. 161 had a diagnosis Alcohol 
      Dependence Syndrome (ADS); 14 patients had a <<dual diagnosis>>. All patients were 
      randomized into 5 groups according to the drugs received. To assess the 
      therapeutic efficacy of drugs, the following scales were used: visual analogue 
      scale (VAS), Montgomery-Asberg Depression Rating Scale (MADRS), Hospital Anxiety 
      and Depression Scale (HADS). The safety of drugs was assessed by the incidence of 
      adverse events (AEs) or serious adverse events (SAEs). RESULTS: The drugs relieve 
      depressive disorders: fluvoxamine by the 7th day of treatment, sertraline, 
      paroxetine, citalopram by the 14th day, fluoxetine by the 30th day of therapy. A 
      significant decrease in the level of anxiety when taking fluvoxamine and 
      citalopram occurs by the 7th day, when taking sertraline and paroxetine - by the 
      14th day, and when taking fluoxetine - by the 30th day. The presence of an 
      anticraving effect in SSRIs is confirmed by the obtained strong and average 
      correlation coefficients between affective disorders and craving for alcohol. The 
      correlation analysis allowed drawing the conclusions about the close connection 
      of presenting features of the affective disorders (depression and anxiety) and 
      craving. The anticraving effect is more expressive in fluvoxamine, sertraline, 
      citalopram and paroxetine. The most common adverse reactions (increased insomnia 
      and anxiety) are observed in: fluoxetine, citalopram, sertraline, paroxetine. 
      Fluvoxamine has the most favorable safety profile. CONCLUSION: SSRIs can be 
      effectively used for the treatment of depressive disorders in alcohol dependence.
FAU - Vinnikova, M A
AU  - Vinnikova MA
AUID- ORCID: 0000-0003-3289-8786
AD  - Moscow Research and Practical Centre on Addictions of the Moscow Department of 
      Healthcare, Moscow, Russia.
AD  - Sechenov First Moscow State Medical University, Moscow, Russia.
FAU - Severtsev, V V
AU  - Severtsev VV
AUID- ORCID: 0000-0001-8712-3561
AD  - Sechenov First Moscow State Medical University, Moscow, Russia.
FAU - Komarov, S D
AU  - Komarov SD
AUID- ORCID: 0000-0002-8807-5909
AD  - Moscow Research and Practical Centre on Addictions of the Moscow Department of 
      Healthcare, Moscow, Russia.
FAU - Vdovin, A S
AU  - Vdovin AS
AUID- ORCID: 0000-0002-9237-4290
AD  - Moscow Research and Practical Centre on Addictions of the Moscow Department of 
      Healthcare, Moscow, Russia.
LA  - rus
PT  - Journal Article
PT  - Randomized Controlled Trial
TT  - Fluvoksamin v terapii depressivnykh rasstroistv pri alkogol'noi zavisimosti: 
      rezul'taty randomizirovannogo otkrytogo sravnitel'nogo issledovaniya.
PL  - Russia (Federation)
TA  - Zh Nevrol Psikhiatr Im S S Korsakova
JT  - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
JID - 9712194
RN  - 0 (Serotonin Uptake Inhibitors)
RN  - 01K63SUP8D (Fluoxetine)
RN  - 0DHU5B8D6V (Citalopram)
RN  - 41VRH5220H (Paroxetine)
RN  - O4L1XPO44W (Fluvoxamine)
RN  - QUC7NX6WMB (Sertraline)
SB  - IM
MH  - *Alcoholism/complications/drug therapy
MH  - Citalopram/adverse effects
MH  - *Depressive Disorder
MH  - Fluoxetine/adverse effects
MH  - Fluvoxamine/adverse effects
MH  - Humans
MH  - Paroxetine
MH  - Selective Serotonin Reuptake Inhibitors/adverse effects
MH  - Sertraline/adverse effects
OTO - NOTNLM
OT  - SSRIs
OT  - alcohol dependence
OT  - anticraving effect
OT  - craving for alcohol
OT  - depression
OT  - depressive disorders
OT  - fluvoxamine
OT  - selective serotonin reuptake inhibitors
EDAT- 2022/01/19 06:00
MHDA- 2022/01/21 06:00
CRDT- 2022/01/18 13:49
PHST- 2022/01/18 13:49 [entrez]
PHST- 2022/01/19 06:00 [pubmed]
PHST- 2022/01/21 06:00 [medline]
AID - 10.17116/jnevro202112112157 [doi]
PST - ppublish
SO  - Zh Nevrol Psikhiatr Im S S Korsakova. 2021;121(12):57-62. doi: 
      10.17116/jnevro202112112157.